893423-62-6

Basic information

• Product Name: N-[2-Chloro-3-formyl-4-pyridinyl]carbamic acid tert-butyl ester
• Synonyms: N-[2-Chloro-3-formyl-4-pyridinyl]carbamic acid tert-butyl ester;CarbaMic acid, N-(2-chloro-3-forMyl-4-pyridinyl)-, 1,1-diMethylethyl ester;N-Boc-4-aMino-2-chloro-3-forMylpyridine;4-(Boc-aMino)-2-chloro-3-pyridinecarbaldehyde;N-(2-chloro-3-forMyl-4-pyridinyl)carbaMic acid 1,1-diMethylethyl ester;tert-butyl N-(2-chloro-3-forMylpyridin-4-yl)carbaMate;ert-Butyl (2-chloro-3-forMylpyridin-4-yl)carbaMate;baMicacid,(2-chloro-3-forMyl-4-pyridinyl)-,1,1-
• CAS NO: 893423-62-6
• Molecular Formula: C₁₁H₁₃ClN₂O₃
• Molecular Weight: 257
• Mol File: 893423-62-6.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 332℃
• Flash Point: 155℃
• Appearance: /
• Density: 1.314
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 11.46±0.70(Predicted)
• CAS DataBase Reference: N-[2-Chloro-3-formyl-4-pyridinyl]carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-[2-Chloro-3-formyl-4-pyridinyl]carbamic acid tert-butyl ester(893423-62-6)
• EPA Substance Registry System: N-[2-Chloro-3-formyl-4-pyridinyl]carbamic acid tert-butyl ester(893423-62-6)

Safety Data

• Hazardous Substances Data: 893423-62-6(Hazardous Substances Data)

Usage

Uses

4-(Boc-amino)-2-chloro-3-pyridinecarbaldehyde is used as a reagent in the synthesis of naphthyridinones as allosteric dual Akt1 and Akt2 inhibitors.

Upstream product

• 14432-12-3 4-Amino-2-chloropyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 68-12-2 N,N-dimethyl-formamide 
• 234108-73-7 (2-chloro-pyridin-4-yl)-carbamic acid tert-butyl ester 
• 594-19-4 tert.-butyl lithium 

Downstream Products

• 908119-05-1 2-[4-(1-azido-1-methylethyl)phenyl]-5-methoxy-3-(2-thienyl)-1,6-naphthyridine 
• 1032350-07-4 4-amino-2-chloronicotinaldehyde trifluoroacetate 
• 1032349-99-7 tert-butyl {1-[4-(5-chloro-3-phenyl-1,6-naphthyrindin-2-yl)phenyl]cyclobutyl}carbamate 
• 917363-98-5 5-hydrazino-3-phenyl-2-(4-{[4-(5-pyrazin-2-yl-4H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridine 
• 917363-81-6 (3-phenyl-2-{4-[4-(5-pyridin-2-yl-4H-[1,2,4]triazol-3-yl)-piperidin-1-ylmethyl]-phenyl}-[1,6]naphthyridin-5-yl)-hydrazine 
• 917363-81-6 5-hydrazino-3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridine 
• 917364-00-2 5-hydrazino-3-phenyl-2-(4-{[4-(5-pyrimidin-2-yl-4H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridine 
• 917363-97-4 5-chloro-3-phenyl-2-(4-{[4-(5-pyrazin-2-yl-4H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridine 
• 917363-99-6 5-chloro-3-phenyl-2-(4-{[4-(5-pyrimidin-2-yl-4H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridine 
• 917363-80-5 5-chloro-3-phenyl-2-{4-[4-(5-pyridin-2-yl-4H-[1,2,4]triazol-3-yl)-piperidin-1-ylmethyl]-phenyl}-[1,6]naphthyridine 
• 917363-80-5 5-chloro-3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridine 
• 917364-08-0 5-hydrazino-3-phenyl-2-(4-{[4-(4H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridine 
• 917364-07-9 5-chloro-3-phenyl-2-(4-{[4-(4H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridine 
• 917364-22-8 tert-butyl({(1R)-1-[4-(3-methyl-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-8-yl)phenyl]ethyl}amino)sulfoniumolate 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS

The present invention provides heterocyclic compounds of formula (I), which are therapeutically useful as CBP/EP300 inhibitors. These compounds are useful in the treatment and/or prevention of diseases or disorders mediated by CBP and/or EP300 in an individual. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising at least one of the compounds of formula (I) or a pharmaceutically acceptable salt, or a stereoisomer or a tautomer, an N-oxide or an ester thereof.

Allosteric inhibitors of Akt1 and Akt2: A naphthyridinone with efficacy in an A2780 tumor xenograft model

A series of naphthyridine and naphthyridinone allosteric dual inhibitors of Akt1 and 2 have been developed. These compounds have been optimized to have potent dual activity against the activated kinase as well as the activation of Akt in cells. One molecu

INHIBITORS OF AKT ACTIVITY

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.